A case of anti-aminoacyl tRNA synthetase (ARS) antibody-positive polymyositis (PM)/dermatomyositis (DM)-associated interstitial pneumonia (IP) successfully controlled with bosentan therapy
A 72-year-old woman was admitted to our hospital and was diagnosed with interstitial pneumonia (IP) associated with amyopathic dermatomyositis (ADM). The patient experienced three acute IP exacerbations in the 7 years that followed, which were each treated and resolved with steroid pulse therapy. Th...
Main Authors: | Tomoyuki Naito, Yosuke Tanaka, MD, PhD, Mitsunori Hino, Akihiko Gemma |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-01-01
|
Series: | Respiratory Medicine Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2213007117300473 |
Similar Items
-
Bosentan for pulmonary hypertension secondary to idiopathic pulmonary fibrosis
by: Naomi Onda, et al.
Published: (2015-01-01) -
Current status of bosentan for treatment of pulmonary hypertension
by: Raja Shahzad, et al.
Published: (2008-01-01) -
Bosentan, a drug used in the treatment of pulmonary hypertension, can prevent development of osteoporosis
by: Duygu Köse, et al.
Published: (2021-07-01) -
Approaches to therapy for pulmonary hypertension: Role of the endothelin receptor antagonist bosentan
by: S N Avdeev
Published: (2015-09-01) -
Bosentan use in pulmonary arterial hypertension: Russian and foreign experience
by: Z S Valieva, et al.
Published: (2017-08-01)